Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Intravenous Immunoglobulin

Research Leaders

9 sponsors active, led by Ruttonjee Hospital, Hong Kong

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Not Applicable (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT01617317Not ApplicableCompletedPrimary

H-IVIG Treatment for Severe H1N1 2009

Showing all 1 trials

Research Network

Common Treatments

  • Intravenous Immunoglobulin1
  • Hyperimmune Intravenous Immunoglobulin1

Active Sponsors

  • Ruttonjee Hospital, Hong Kong1
  • Caritas Medical Centre, Hong Kong1
  • HK Red Cross Blood Transfusion Service, Hong Kong1
  • United Christian Hospital1
  • Pamela Youde Nethersole Eastern Hospital1

Top Investigators

Activity Timeline